Torrid Holdings (CURV) +28% — Strong Results + 2026 Outlook

‍

‍Torrid surged 28% in one day after reporting better-than-expected fourth-quarter and full-year 2025 results, while also issuing 2026 guidance above expectations. The company said full-year adjusted EBITDA reached $63.6 million and guided 2026 sales to $940 million–$960 million.Investors reacted positively because the report showed signs that the business is stabilizing. Management highlighted store closures, growth from newer brands, and improving early first-quarter trends as reasons for stronger confidence going forward.

‍

Ovid Therapeutics (OVID) +14% — FDA Designation + Pipeline Update

‍

‍Ovid rose 14% after announcing that OV329 received Breakthrough Therapy designation, alongside new data and broader pipeline updates. The company said OV329 continued to show a favorable safety profile and is advancing into Phase 2 development.Investors reacted positively because the designation strengthens the regulatory path for OV329 and improves the program’s commercial outlook. The update also showed continued pipeline progress and a cash position expected to fund operations into late 2028.

‍

Swarmer (SWMR) +500% — Small IPO Drives Huge Debut

‍

‍Swarmer surged more than 500% in its public market debut after pricing a small $15 million IPO with limited available shares. The stock opened far above its IPO price and continued climbing through its first trading day.Investors piled in because Swarmer is tied to the high-interest defense drone and AI theme. The company’s small float, combined with strong demand for defense-related names, helped fuel the sharp move higher.